Ligand Pharmaceuticals Incorporated Stock News

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Ligand Pharmaceuticals (LGND) or Illumina (ILMN). But which of these two stocks offers value

After impressive quarterly results on Wednesday, here are two highly-ranked Zacks Medical sector stocks that investors may want to consider.

Ligand Pharmaceuticals (LGND) reports encouraging third-quarter results as earnings and sales beat estimates. Management raises the 2023 financial outlook.

FATE reports better-than-expected third-quarter 2023 financial results, driven by lower operating expenses. The stock rises about 5% in the after-market hours.

Ligand Pharmaceuticals Inc. (NASDAQ:LGND ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Simon Latimer - Head-Investor Relations Todd Davis - Chief Executive Office

Although the revenue and EPS for Ligand (LGND) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Stre

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $53.30, indicating a +1.93% shift from the previous trading day.

GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales on the back of strong RSV vaccine sales.

Ligand (LGND) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Ligand Pharmaceuticals (LGND) or Illumina (ILMN). But which of these two companies is the bes

SAN DIEGO--(BUSINESS WIRE)-- #earnings--Ligand To Report Third Quarter 2023 Financial Results On November 8.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

In the closing of the recent trading day, Ligand Pharmaceuticals (LGND) stood at $52.09, denoting a -1.31% change from the preceding trading day.

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Ligand Pharmaceuticals (LGND) or Illumina (ILMN). But which of these two stocks presents inve